Investors shouldn't rush to buy the stock based on rosy short-term price targets.To say that Exact Sciences (EXAS 3.19%) hasn't performed well on the stock market this year would be an understatement. Shares of the cancer-focused biotech are down by 41%. However, the healthcare company still has some fans on Wall Street.Cathie Wood is one of them. The investment firm she heads, Ark Invest, holds over 330,000 shares of Exact Sciences. She isn't the only one who isn't giving up on the company. Analysts on Wal ...